model updat steadi slow
progress pt
updat sales/ep estimate cc
sell day sd
off-set higher model gm/om/tax rate
prior estimate compar
consensu guidanc
 exhibit pt
base average suggest rel valuat framework
estim chang lower sales/ep
cc cc sd adj cc
 lower revenu impact loss bone cement
supplier exhibit model gm/om/tax rate prior
sale estim compar consensu
valuat thesi risk lower price target base
averag dcf valu assum top-lin acceler
ultim improv pre-tax margin
employ discount rate termin
growth rate rel valuat framework valu rel
valuat framework regress year top-lin expect rel
forward multipl larger cap med tech compani period
incorpor compound-annual-growth-rate estim suggest rel
forward multipl multipli day averag
market multipl yield target forward multipl
multipli estim ep month henc arriv
rel valuat valu view suit
longer term holder patienc stabil core
busi diversif effort move compani higher market
wagr loos speak dcf captur promis zbh intrins
valu presum good execut success diversif wherea
rel valuat captur current realiti remain buy rate
valuat remain unchalleng manag seem make
right move improv perform part due key new
product rosa robot seem creat favor risk reward
oper perform improv diversif becom tangibl
credit may ascrib intrins valu continu pg
tr target
risk includ execut misstep inclus failur remedi product suppli shortfal
lead continu under-perform vs end market sluggish anticip major joint
market issuanc fda warn letter could interfer suppli and/or new product
introduct and/or new product introduct misstep inclus rosa tka robot
page
page
page
page
million except per share interest expens inc analysisgross cmf sale sale cc/sd/divest sale inc inc
zimmer lead player musculoskelet devic segment player hip
ww share knee meaning presenc musculoskelet categori dental
cmf/thorac surgic sport medicin extrem trauma
spine ex-ldrh spun parent august headquart
believ suit longer term holder patienc stabil
core busi diversif effort move compani higher market wagr
loos speak dcf captur promis zbh intrins valu presum good execut
success diversif wherea rel valuat captur current realiti remain
buy rate valuat remain unchalleng manag seem make right
move improv perform part due key new product rosa robot
seem creat favor risk reward oper perform improv diversif
becom tangibl credit may ascrib intrins valu
valuat risk
price target base averag dcf valu assum top-
line acceler ultim improv pre-tax margin
employ discount rate termin growth rate rel
valuat frame valu rel valuat framework regress year top-lin expect
rel forward multipl larger cap med tech compani period
incorpor compound-annual-growth-rate estim suggest rel forward multipl
multipli day averag market multipl yield target forward multipl
multipli estim ep month henc arriv rel
valuat valu risk includ execut misstep inclus failur remedi
product suppli shortfal lead continu under-perform vs end market sluggish
anticip major joint market issuanc fda warn letter could interfer suppli
and/or new product introduct and/or new product introduct misstep inclus rosa tka
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
